Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds
Authors:
- INSIGHT-AD study groupIGINSIGHT-AD study group
- Marie-Odile HabertMHMarie-Odile Habert
- 7 December 2017
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 32 (2) , 75-86
Abstract
Our aim is to validate the process steps implemented by the French CATI platform to assess amyloid status, obtained from 18F-Florbetapir PET scans, in a cohort of 318 cognitively normal subjects participating in the INSIGHT-preAD study. Our objective was to develop a method with partial volume effect correction (PVEC) on untransformed PET images, using an automated pipeline (“RACHEL”) adapted to large series of patients and including quality checks of results.Keywords
Funding Information
- IHU-A-ICM
- French Foundation Plan-Alzheimer
- AXA Research Fund
- Fondation Université Pierre et Marie Curie
- Pfizer
- Avid/Lilly
- Investissement d’Avenir from the Ministry of Research
This publication has 25 references indexed in Scilit:
- CATI: A Large Distributed Infrastructure for the Neuroimaging of CohortsNeuroinformatics, 2016
- Optimization of brain PET imaging for a multicentre trial: the French CATI experienceEJNMMI Physics, 2016
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteriaAlzheimer's & Dementia, 2016
- Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's DiseaseThe Journal of Neuroscience, 2015
- Intrinsic Connectivity Identifies the Hippocampus as a Main Crossroad between Alzheimer’s and Semantic Dementia-Targeted NetworksNeuron, 2014
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyThe Lancet Neurology, 2012
- Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal SubjectsJournal of Nuclear Medicine, 2012
- Use of Florbetapir-PET for Imaging β-Amyloid PathologyJAMA, 2011
- In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)Journal of Nuclear Medicine, 2010